Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DC-CIK Immunotherapy + S-1 in Advanced Pancreatic Cancer
NCT01781520Phase 2Completed
- Sponsor
- Capital Medical University
- Start
- Jun 2013
- Primary completion
- May 2016
- Modality
- Prophylactic Vaccines, Whole Cell Cancer Vaccines, Dendritic Cell Vaccines
- Countries
- 1
01
Overview
Phase 2, open-label trial of dendritic cell vaccine + cytokine-induced killer cells in pancreatic cancer (PC) (4 arms), sponsored by Capital Medical University. Primary endpoint: Treatment toxicity at 4 years. Started Jun 2013; status: completed.
02
Drugs
dendritic cell vaccine + cytokine-induced killer cells
03
Conditions
pancreatic cancer (PC)
Beyond the preview
Go deeper on NCT01781520.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01781520.